BofA analyst Jason Zemansky lowered the firm’s price target on BioMarin (BMRN) to $102 from $103 and keeps a Buy rating on the shares following what the firm calls “an okay 3Q print.” The company tweaked the 2027 revenue outlook, now offering a range of $3.6B-$4B versus $4B previously with the range depending on Voxzogo competition scenarios, notes the analyst, who doesn’t expect the long-term guidance update to come as an investor surprise given that management communicated plans to update last quarter and the low end of the range aligns with consensus.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin price target lowered to $55 from $60 at H.C. Wainwright
- BioMarin Pharmaceutical: Strong Growth Potential Amidst Competitive Challenges
- BioMarin price target lowered to $70 from $90 at Wells Fargo
- BioMarin price target lowered to $80 from $86 at Barclays
- BioMarin Reports Strong Q3 2025 Revenue Growth